Cytokinetics, Incorporated
CYTK
Rank in Stocks
#2300
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Share Price
$62.31
Last synced: 2026-10-16
Market Cap
$8.66B
Change (1 day)
-2.51%
Change (1 year)
6.63%
Country
US
Trade Cytokinetics, Incorporated (CYTK)
Category
Healthcare
Dividend history for Cytokinetics, Incorporated (CYTK)
Cytokinetics, Incorporated (stock symbol: CYTK) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Cytokinetics, Incorporated (CYTK) from 2026 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
